Skip to content

Study · Not a test of the peptide alone · 2013

3 results

In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.

Micheletto F, Dalla Man C, Kolterman O, Chiquette E, Herrmann K, Schirra J, Kovatchev B, Cobelli C

Diabetes technology & therapeutics18 Jul 2013Cited by 18 (Europe PMC)

PMID23865841 (opens in a new tab)PMCIDPMC3781117 (opens in a new tab)DOI10.1089/dia.2013.0054 (opens in a new tab)PepBankPUB-23865841
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In virtual adults with T1DM, simulations estimated an optimal pramlintide-to-insulin ratio of 9 μg/U.

    In plain wordsComputer simulations estimated an optimal pramlintide-to-insulin ratio of 9 μg/U.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableOptimal pramlintide-to-insulin ratio
    Study

    n: not reported in source

    Virtual adult type 1 diabetes patients
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Pramlintide-to-insulin ratio
    9 μg/U
    optimal simulated ratio

    Source sentences

    Summary
    In silico experiments estimated the optimal P/I ratio to be 9 μg of pramlintide per unit (U) of insulin.
    1 context sentence
    Summary · context
    We present an in silico approach to the design of optimal pramlintide-to-insulin (P/I) ratios, using our computer simulator of the human metabolic system, with a population of virtual adult type 1 diabetes mellitus patients and with individual parameters modified to account for the dynamic effects of pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In virtual adults with T1DM, ratios of 8 and 10 μg/U were predicted to perform similarly to the optimal 9 μg/U ratio.

    In plain wordsComputer simulations predicted that ratios of 8 and 10 μg/U would perform similarly to the optimal 9 μg/U ratio.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableAlternative ratio performance
    Study

    n: not reported in source

    Virtual adult type 1 diabetes patients
    Comparator
    Optimal simulated ratio of 9 μg/U
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Additional simulations narrowing the investigated range indicated that P/I ratios of 8 and 10 μg/U would achieve similar performance.
    1 context sentence
    Summary · context
    We present an in silico approach to the design of optimal pramlintide-to-insulin (P/I) ratios, using our computer simulator of the human metabolic system, with a population of virtual adult type 1 diabetes mellitus patients and with individual parameters modified to account for the dynamic effects of pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 03Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In virtual adults with T1DM, simulations suggested approximately 21% lower insulin boluses at a pramlintide-to-insulin ratio of 9 μg/U.

    In plain wordsComputer simulations suggested approximately 21% lower insulin boluses at a pramlintide-to-insulin ratio of 9 μg/U.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseInsulin bolus reduction
    Study

    n: not reported in source

    Virtual adult type 1 diabetes patients
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Moreover, simulation results suggested that in clinical trials, insulin boluses should be reduced by approximately 21% at a P/I ratio of 9 μg/U to account for the effects of pramlintide and avoid postprandial hypoglycemia.
    1 context sentence
    Summary · context
    We present an in silico approach to the design of optimal pramlintide-to-insulin (P/I) ratios, using our computer simulator of the human metabolic system, with a population of virtual adult type 1 diabetes mellitus patients and with individual parameters modified to account for the dynamic effects of pramlintide.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.